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Background: To determine at what stage during gastric carcinogenesis Epstein-Barr virus (EBV) enters the
gastric epithelial cells, the presence of EBV was investigated in two pathogenetically related but distinct
forms of adenocarcinoma of the stomach—gastric carcinoma of the intact stomach (GCIS) and gastric
stump carcinoma (GSC)—and their presumed precursor lesions.
Patients and methods: Eleven patients with EBV positive GCIS and eight patients with EBV positive GSC,
demonstrated by the highly sensitive EBV encoded RNA 1/2 (EBER1/2) RNA in situ hybridisation (RISH)
technique, were studied. Paraffin wax embedded tissue available from preoperative gastric biopsies and
tumour adjacent tissue from the resection specimens containing normal gastric mucosa, inflamed gastric
mucosa, and preneoplastic lesions (intestinal metaplasia and dysplasia) was investigated by EBER1/2
RISH, in addition to EBV nuclear antigen 1 (EBNA-1) and latent membrane protein 1 (LMP-1)
immunohistochemistry (IHC).
Results: In both GCIS and GSC and their precursor lesions EBER1/2 transcripts were restricted to the
carcinoma cells. In addition, positivity of EBNA-1 IHC was also restricted to the tumour cells. IHC for LMP-1
was negative in all cases tested.
Conclusions: The absence of EBER1/2 transcripts in preneoplastic gastric lesions (intestinal metaplasia
and dysplasia) and their presence in two distinct types of gastric carcinoma strongly suggest that EBV can
only infect neoplastic gastric cells and thus is a late event in gastric carcinogenesis.
W
orldwide, gastric carcinoma is one of the leading
causes of cancer related mortality and clinical
prognosis is very poor.1 The most commonly
accepted hypothesis of gastric carcinogenesis of intestinal
type carcinoma comprises a sequence of presumed precursor
lesions: chronic atrophic gastritis (CAG) and intestinal
metaplasia (IM). This has been shown to develop upon
Helicobacter pylori infection, and is thought to lead to dysplasia
and intestinal type gastric carcinoma.1 2 This is in contrast to
the other major type of gastric carcinoma—diffuse type
carcinoma—of which no precursor lesions have been
identified to date.
During the past decade, accumulating evidence has
indicated a role for the human pathogenic Epstein-Barr virus
(EBV) in gastric carcinogenesis.3–6 EBV is found in approxi-
mately 10% of gastric adenocarcinomas not otherwise
specified and it is estimated that worldwide each year
50 000–75 000 new cases of EBV carrying gastric carcinoma
occur.5 In addition, 35% of gastric stump carcinomas (GSCs)
are associated with EBV.7 GSCs are carcinomas that develop
years after surgery for peptic ulcer disease, with an increased
risk for men and Billroth II reconstruction. During the
neoplastic process various precursor lesions of the intestinal
type of gastric carcinoma are observed.8 9
‘‘The knowledge of how and at what time point Epstein-
Barr virus (EBV) enters the gastric epithelium would help to
determine the role of EBV in gastric carcinogenesis’’
However, the role of EBV in gastric carcinogenesis is not
yet completely understood. We have recently shown that EBV
carrying gastric carcinomas express the transforming BARF1
gene of EBV and that EBV carrying gastric carcinomas are
characterised by distinct chromosomal aberrations.10 11 These
data strongly argue for an important role for EBV in gastric
carcinogenesis.
More than 30 years after the first report of EBV DNA in an
epithelial malignancy (nasopharyngeal carcinoma),12 it
remains unclear how EBV enters epithelial cells, because
the EBV receptor CD21 is not expressed on epithelial cells.
Similarly, it is not known how EBV enters the gastric
epithelium or carcinoma cells. It has been reported that EBV
is monoclonally present in all gastric carcinoma cells.13 14 The
knowledge of how and at what time point EBV enters the
gastric epithelium would help to determine the role of EBV in
gastric carcinogenesis.
Previous reports concerning the detection of EBV in the
presumed gastric carcinoma precursor lesions CAG, IM, and
dysplasia are highly controversial. Some authors find EBV
restricted to the carcinoma cells,13–15 whereas others report
EBV in the precursor lesions and in the carcinoma cells.3 16–18
In an attempt to determine the stage of gastric carcinogen-
esis at which EBV putatively enters the gastric epithelium we
performed the highly sensitive EBV encoded RNA 1/2
(EBER1/2) RNA in situ hybridisation technique (EBER1/2
RISH), which has been shown to be superior to EBV DNA in
situ hybridisation.19 The material used included resection
specimens of gastric carcinoma and gastric biopsies of
patients after Billroth II resection and preoperative biopsies
of patients with gastric carcinoma in the intact stomach
(GCIS) comprising non-neoplastic, preneoplastic, and neo-
plastic gastric mucosa. EBER1/2 RISH was performed on all
paraffin wax blocks that were available for each case,
Abbreviations: CAG, chronic atrophic gastritis; EBER, Epstein-Barr
virus encoded RNA; EBNA, Epstein-Barr virus nuclear antigen; EBV,
Epstein-Barr virus; GCIS, gastric carcinoma of the intact stomach; GSC,
gastric stump carcinoma; IHC, immunohistochemistry; IM, intestinal
metaplasia; LMP-1, latent membrane protein 1; RISH, RNA in situ
hybridisation
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including normal gastric epithelium, CAG, IM, dysplasia, and
carcinoma. In addition, we applied immunohistochemistry
(IHC), for the EBV proteins—latent membrane protein 1
(LMP-1) and EBV nuclear antigen 1 (EBNA-1)—and the
EBV receptor (CD21).
MATERIALS AND METHODS
Clinical materials
EBV carrying GCIS
Samples from 11 EBV carrying GCIS patients were collected
at the department of pathology, Vrije Universiteit medical
centre Amsterdam, The Netherlands. These carcinomas were
tested for the presence of EBV by EBER1/2 RISH, and data on
10 of these carcinomas have previously been described.10 All
paraffin wax embedded material available from these cases—
that is, all parts of the tumour and non-neoplastic tissue from
the resection specimen and the preoperative biopsy
(n = 7)—was submitted to EBER1/2 RISH. In total, 29
normal gastric epithelia, 10 with chronic atrophic gastritis, 18
with intestinal metaplasia, two low grades, and one moderate
dysplasia were evaluated. The diagnoses were confirmed by
an experienced gastrointestinal pathologist (GJAO). Table 1
summarises the clinicopathological data of these 11 gastric
carcinomas. All tumours were adenocarcinomas not other-
wise specified. No lymphoepithelial-like carcinomas were
studied.
EBV carrying GSC
Samples from eight EBV carrying GSC patients, as deter-
mined by EBER1/2 RISH, were obtained from the department
of pathology, Academic medical centre, University of
Amsterdam, The Netherlands. Preceding biopsies (n = 8),
containing normal gastric epithelium, IM, dysplasia, and
carcinoma, collected in the context of a longstanding follow
up were also submitted to EBER1/2 RISH. In addition, gastric
tissues from the resection specimens with IM and dysplasia
adjacent to EBV positive gastric carcinomas were also
submitted to EBER1/2 RISH. In total, 24 normal gastric
epithelia, five with CAG, 14 with IM, and three low grade
dysplasias were evaluated. The diagnoses were confirmed by
an experienced gastrointestinal pathologist (GJAO). Table 2
summarises the clinicopathological data of the patients with
GSC. No lymphoepithelial-like carcinomas were studied.
EBER1/2 and b actin RISH
RISH was performed for the EBER 1/2 transcripts and the
b actin target as described previously.20 Paraffin wax
embedded tissues from preoperative biopsies and the
gastrectomy of the tumour and adjacent non-neoplastic
mucosa of EBV carrying GCIS and GSC samples were
subjected to the non-radioactive EBER1/2 RISH using
digoxygenin labelled antisense and sense EBER1/2 probes
as described previously.20
Table 1 Summary of preoperative biopsy and resection data of patients with an EBV carrying gastric carcinoma of the intact
stomach
Case Sex
Preoperative biopsy Resection
Year Diagnosis EBV Year Diagnosis EBV Laure´n type Diff. Loc.
1 F 1985 Carcinoma + 1986 Carcinoma (36) + I Mo Cardia
CAG 2 IM (26) 2
IM 2 NE (36) 2
LGD 2
MD 2
2 M 1986 Carcinoma + 1986 Carcinoma (36) + I P Cardia
IM 2 IM (26) 2
NE 2 NE (26) 2
3 M 1987 Carcinoma + 1987 Carcinoma (26) + I P Cardia
NE 2 IM (16) 2
IM 2 NE (26) 2
LGD 2
4 F 1989 Carcinoma + 1989 Carcinoma (26) + D P Antrum
CAG (16) 2
NE (16) 2
5 M 1994 Carcinoma + 1994 Carcinoma (26) + I P Cardia
IM 2 CAG (16) 2
NE 2 NE (36) 2
6 M 1993 Carcinoma + 1993 Carcinoma (26) + I P Antrum
NE 2 IM (16) 2
CAG (16) 2
NE (26) 2
7 F NB 1991 Carcinoma (26) + I P Corpus
CAG (16) 2
NE (16) 2
8 M NB 1984 Carcinoma (26) + I P Cardia
IM (16) 2
CAG (16) 2
NE (26) 2
9 M NB 1984 Carcinoma (56) + I P Cardia
IM (36) 2
CAG (26) 2
NE (76) 2
10 M NB – – 1983 Carcinoma (36) + I P Cardia
IM (26) 2
NE (26) 2
11 M 2003 Carcinoma + 2003 Carcinoma (26) + I P Cardia
IM (26) 2
CAG (26) 2
CAG, chronic atrophic gastritis; D, diffuse type; Diff., differentiation; EBV, Epstein-Barr virus; F, female; I, intestinal type; IM, intestinal metaplasia; Loc.,
localisation; LGD, low grade dysplasia; M, male; MD, moderate dysplasia; NB, no biopsy available; NE, normal epithelium; P, poorly.
The presence of EBV was tested by EBV encoded RNA in situ hybridisation; the numbers in parenthesis indicate the frequency of the lesion tested for EBV.
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Immunohistochemistry
To detect EBV specific proteins, which are known to be
expressed in EBV associated epithelial malignancies,19 mono-
clonal antibodies against LMP-1 (CS1-4; Dako, Glostrup,
Denmark) and EBNA-1 (2B4-1; a kind gift from Dr Gra¨sser,
Homburg, Germany) were used. Detection of the EBV
receptor was performed with a monoclonal anti-CD21 anti-
body (Dako; clone 1F8). All antibodies were visualised with
an avidin–biotin–horseradish peroxidase complex and dia-
minobenzidine/H2O2 staining method, as described pre-
viously by our laboratory.20–22
RESULTS
EBV carrying GCIS
EBER1/2 positivity was found in all tumour cells of the 11
EBV carrying GCISs, both in the resection specimens and in
the preoperative biopsies (table 1; fig 1A).10 EBER1/2
transcripts were never found in the mucosa adjacent to these
EBV carrying GCISs, comprising normal gastric tissue
(n = 29), CAG (n = 10), IM (n = 18), and dysplasia
(n = 3) (table 1). RISH for b actin performed on corre-
sponding tissue sections revealed sufficient RNA quality. IHC
for EBNA-1 and LMP-1 expression on representative tissue of
10 of the cases showed the presence of EBNA-1 protein in the
carcinoma cells in four of 10 cases (fig 1B),10 whereas no
LMP-1 staining was found in the neoplastic cells or non-
neoplastic epithelial cells (fig 1C). EBNA-1 expression was
not detected in the adjacent gastric mucosa of the four
EBNA-1 positive gastric carcinomas, neither in the normal
epithelium (n = 13) nor in areas of IM (n = 3).
Moreover, CD21 IHC was performed on EBV carrying GCIS
and its precursor lesions. No positive staining was found in
non-neoplastic or neoplastic epithelial cells (fig 1 D), whereas
positive staining was seen in dendritic cells and B cells.
Gastric stump carcinomas
Specific nuclear EBER1/2 RISH transcripts were restricted to
the tumour cells of GSCs in the gastrectomy specimens and
the preceding biopsies (n = 17) (table 2, fig 2). No EBER1/2
transcripts were detected in normal gastric epithelium
(n = 24), CAG (n = 5), or IM (n = 14) in the mucosa
adjacent to the carcinoma tissue of both the gastrectomy
tissue (fig 2A and B) and the preoperative biopsies (table 2).
In three cases (patients 6, 7, and 8), biopsy material was
available 4, 18, and 18 years before the diagnosis gastric
carcinoma, respectively. These biopsies all contained low
grade dysplasia. In all of these cases, EBER1/2 RISH was
negative in the preceding biopsy, both in the normal and the
dysplastic epithelium (table 2)
The resection cases were tested for LMP-1 expression by
immunohistochemistry (n = 8). No positive staining for
LMP-1 was detected in the carcinoma cells, the preneoplastic
lesions, or non-neoplastic gastric epithelium.
DISCUSSION
Growing evidence of a role for EBV in gastric carcinogenesis
derives from the following observations: EBV carrying gastric
carcinomas harbour distinct chromosomal aberrations and
are characterised by a unique transcription pattern resem-
bling but not identical to nasopharyngeal carcinomas.10 11 In
addition, EBV carrying gastric carcinomas display specific
clinical features compared with EBV negative gastric carci-
nomas.22a Therefore, the purpose of our present study was to
determine the stage of gastric carcinogenesis at which EBV
possibly enters the gastric epithelium. Although not firmly
established, the present hypothesis on gastric carcinogen-
esis—of at least the intestinal type of gastric carcinoma—
comprises the sequence of gastritis, CAG, IM, dysplasia, and
invasive carcinoma.2 Therefore, we investigated the presence
of EBER1/2 transcripts in these presumed precursor lesions
Table 2 Summary of preoperative biopsy and resection data of patients with EBV carrying gastric stump carcinoma
Case Sex
Preoperative biopsy Carcinoma resection
Year Diagnosis EBV
Carcinoma
surgery Diagnosis EBV
Laure´n
type PU surgery
1 M 1981 Carcinoma + 1982 Carcinoma (26) + I 1946
IM (36) 2
NE (36) 2
2 M 1979 Carcinoma + 1979 Carcinoma (26) + I 1957
NE 2 IM (46) 2
LGD (16) 2
NE (46) 2
3 M 1977 Carcinoma + 1980 Carcinoma (16) + I 1954
CAG 2 IM (16) 2
NE 2 NE (16) 2
4 M 1979 Carcinoma + 1980 Carcinoma (26) + I 1954
NE 2 IM (16) 2
CAG (16) 2
NE (26) 2
5 M 1978 Carcinoma + 1979 Carcinoma (16) + I 1951
IM (26) 2
CAG (16) 2
NE (36) 2
6 M 1976 LGD 2 1980 Carcinoma (26) + I 1942
NE 2 CAG (26) 2
NE (26) 2
7 M 1978 LGD 2 1996 Carcinoma (16) + I 1955
NE 2 IM (16) 2
NE (16) 2
8 M 1976 LGD 2 1994 Carcinoma (16) + I 1944
NE 2 IM (26) 2
NE (26) 2
CAG, chronic atrophic gastritis; EBV, Epstein-Barr virus; F, female; IM, intestinal metaplasia; LGD, low grade dysplasia; M, male; MD, moderate dysplasia; NE,
normal epithelium; PU, peptic ulcer.
The presence of EBV was tested by EBV encoded RNA in situ hybridisation; the numbers in parenthesis indicate the frequency of the lesion tested for EBV.
EBV is a late event in gastric carcinogenesis 489
www.jclinpath.com
and neoplastic gastric epithelium of EBV carrying GCIS and
GSC samples. Because the viral genome is present in limited
numbers in most EBV associated malignancies, DNA ISH is
not very sensitive. Therefore, we used EBER RISH, a
technique that measures EBER1/2 RNAs, which are highly
abundant in most EBV carrying tumour cells, and is the most
sensitive method to demonstrate the presence of EBV.19 This
is the first study in which two types of gastric carcinoma
(GCIS and GCS) were investigated and all available paraffin
embedded material from each case was analysed.
Specific nuclear EBER1/2 transcripts were found only in
the carcinoma cells of both types of gastric carcinoma, and
not in the adjacent normal, metaplastic, or dysplastic
epithelia. In addition, EBV was detected in none of the
normal or dysplastic epithelia of the preceding biopsies in
EBV positive GSC.
In addition to EBER1/2 RISH, IHC for EBNA-1 and LMP-1
was carried out. Expression of EBNA-1 was restricted to gastric
carcinoma cells (GCIS). No expression was found in the
presumed precursor lesions of gastric carcinoma. EBNA-1
protein expression as measured by IHC was not detected in
the cases of EBV positive gastric carcinoma probably
because of the low content of EBNA-1 and the lower
sensitivity of IHC in comparison with EBER1/2 RISH.22
Interestingly, LMP-1 expression was not found in the EBV
positive carcinomas and their precursor lesions, which is in
line with previous observations.23 24
‘‘Our data strongly suggest that Epstein-Barr virus is only
present in susceptible cells of gastric carcinomas but not in
its supposed precursor lesions’’
Our results agree with other studies in which EBER
transcripts have not been detected in adjacent precursor
lesions, such as IM.13–15 23 However, some reports describe the
presence of EBV in dysplasia,3 16 and some even in IM and
CAG.17 18 There are several reasons for these discrepancies.
First, the problem associated with diagnosing dysplasia and
carcinoma is well recognised.2 In addition, dysplasias
adjacent to carcinomas are difficult to distinguish from local
carcinoma spread. The second reason is the use of different
techniques and the interpretation of the results. Yanai and
co-workers reported EBNA-1 and LMP-1 staining in CAG and
IM.17 Because we used the same antibodies for EBNA-1 and
LMP-1 this discrepancy is surprising. However, in our
longstanding experience with these antibodies,10 21 22 we have
found that crossreactivity can occur and that the interpreta-
tion of positive IHC results should always be done in the
context of transcript analysis by reverse transcription poly-
merase chain reaction.10 22
It is of interest that EBV carrying GCIS and EBV carrying
GSC did not differ with respect to the distribution of EBER1/2
transcripts. Although the carcinogenesis of both of these
entities is closely linked to H pylori, in GSC bile reflux is
thought to play a major role in the multistep process of
gastric carcinogenesis.
The fact that the expression of EBER1/2 transcripts and
EBNA-1 protein is restricted to the tumour cells in EBV
carrying GCIS and GSC strongly indicates that EBV enters the
gastric epithelium at a late stage of the multistep process of
gastric carcinogenesis. In addition, we showed that CD21, the
EBV receptor, is not present in normal, preneoplastic, and
neoplastic gastric cells. This is in line with the observations of
others,25–27 and suggests the existence of an alternative EBV
receptor on epithelial cells,28 29 or an alternative route of entry
of EBV into epithelial cells.
Because dysplasias are EBER1/2 RISH negative and all
tumour cells carry EBV it is highly likely that EBV infects a
neoplastic gastric epithelial cell, providing a growth advan-
tage to the EBV positive tumour cell. Alternatively, EBV
might infect a highly dysplastic gastric epithelial cell,
transforming it into a carcinoma cell. Another explanation
might be that gastric carcinogenesis develops through an as
yet unknown route, in which the morphology of the
precursor lesion has not yet been identified. However, all
hypotheses point to a role for EBV late in the process of
gastric carcinogenesis and explain why monoclonal EBV has
been reported in all tumour cells of EBV carrying GCISs and
GSCs.
Figure 1 (A) Epstein-Barr virus (EBV)
encoded RNA 1/2 (EBER1/2) RNA in
situ hybridisation in a gastric carcinoma
of the intact stomach revealing specific
EBER1/2 transcripts (dark) in the nuclei
of the tumour cells. A corresponding
slide shows (B) tumour cells with specific
nuclear expression of EBV nuclear
antigen 1 (dark brown), whereas (C)
staining for latent membrane protein 1
is negative. (D) Expression of CD21
(brown) is restricted to dendritic cells,
whereas the overlying gastric
epithelium is negative.
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In summary, our data strongly suggest that EBV is only
present in susceptible cells of gastric carcinomas but not in its
supposed precursor lesions. This suggests that EBV enters the
gastric epithelium at a late stage of the multistep carcino-
genic process and that EBV plays a role late in the process of
gastric carcinogenesis. This is strengthened by the demon-
stration of restricted EBV transcription in the tumour cells of
two pathogenetically related but distinct models of gastric
carcinogenesis.
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Take home messages
N Epstein-Barr virus (EBV) encoded RNA 1/2 (EBER1/2)
transcripts were found in gastric carcinoma of the intact
stomach (GCIS) and gastric stump carcinoma (GSC)
but not in preneoplastic gastric lesions (intestinal
metaplasia and dysplasia)
N This suggests that EBV can only infect neoplastic gastric
cells and thus is a late event in gastric carcinogenesis
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